Table 3.
Multivariate analysis of prognostic factors for locoregional recurrence, distant metastasis, disease-free survival and overall survival.
| Characteristics | LRR | DM | DFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| Hazard ratio(95%CI) | P | Hazard ratio(95%CI) | P | Hazard ratio(95%CI) | P | Hazard ratio(95%CI) | P | |
| Treatment period (years) | ||||||||
| 2008–2013 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 2014–2016 | 0.56 (0.28–1.11) | .095 | 0.67 (0.46–0.98) | .039 | 0.67 (0.47–0.97) | .033 | 0.67 (0.50–1.11) | .106 |
| Age (years) | ||||||||
| <40 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| ≥40 | 0.63 (0.35–1.11) | .109 | 0.57 (0.41–0.79) | .001 | 0.58 (0.42–0.80) | .001 | 0.75 (0.50–1.11) | .151 |
| Stage | ||||||||
| II–IIIA | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| IIIB–IIIC | 1.41 (0.85–2.33) | .180 | 1.97 (1.47–2.64) | <.001 | 2.00 (1.51–2.65) | <.001 | 2.27 (1.62–3.17) | <.001 |
| Lymphovascular invasion | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.48 (0.87–2.50) | .147 | 1.17 (0.86–1.60) | .312 | 1.19 (0.88–1.61) | .245 | 1.29 (0.90–1.84) | .159 |
| Hormonal receptor | ||||||||
| Negative | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Positive | 1.54 (0.62–3.78) | .351 | 0.62 (0.35–1.13) | .796 | 1.06 (0.58–1.93) | .849 | 0.95 (0.49–1.85) | .876 |
| Neoadjuvant chemotherapy | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.41 (0.82–2.42) | .213 | 1.33 (0.97–1.84) | .078 | 1.39 (1.02–1.89) | .036 | 1.70 (1.19–2.42) | .003 |
| Hormonal therapy | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 0.33 (0.14–0.75) | .009 | 0.62 (0.35–1.13) | .118 | 0.61 (0.35–1.07) | .087 | 0.44 (0.23–0.84) | .013 |
| HER2 and trastuzumab | .011 | .002 | <.001 | .338 | ||||
| HER2− | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| HER2+ + T | 0.76 (0.36–1.58) | .458 | 0.65 (0.42–1.00) | .054 | 0.68 (0.45–1.03) | .068 | 0.67 (0.41–1.08) | .105 |
| HER2+ − T | 2.18 (1.22–3.90) | .008 | 1.61 (1.12–2.32) | .010 | 1.71 (1.21–2.43) | .003 | 1.38 (0.91–2.10) | .134 |
LRR, locoregional recurrence; DM, distant metastasis; DFS, disease-free survival; OS, overall survival; HER2, human epidermal growth factor receptor 2; HER2−, HER2-negative; HER2+ + T, HER2-positive with trastuzumab; HER2+ − T, HER2-positive without trastuzumab.